Skip to content

Study · Randomized controlled trial · n = 15 · 2025

6 results

Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial.

Petković-Dabić J, Binić I, Carić B, Božić L, Umičević-Šipka S, Bednarčuk N, Dabić S, Šitum M, Popović-Pejičić S, Stojiljković MP, Škrbić R

Biomolecules1 Jan 2025Cited by 35 (Europe PMC)

PMID39858442 (opens in a new tab)PMCIDPMC11763288 (opens in a new tab)DOI10.3390/biom15010046 (opens in a new tab)PepBankPUB-39858442
Download PDFPubMedAsk about this study
Jump to 6 results

Summary

Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2-3% of the world's population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory parameters such as C-reactive protein (CRP), cytokines and homocysteine, which vary with disease activity. The objective of this clinical study was to investigate the effect of GLP-1 receptor agonist semaglutide therapy on pro-inflammatory factors in the serum and the severity of the clinical picture of psoriasis in obese patients with type 2 diabetes mellitus (T2DM) on chronic metformin therapy. This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16). The results demonstrated that the severity of the clinical picture of psoriasis, determined by the Psoriasis Area and Severity Index (PASI) score, was significantly better after the administration of semaglutide (the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; p = 0.002). Also, the quality of life in the group of patients who received the drug, measured by the Dermatology Life Quality Index (DLQI), improved significantly after 3 months (a median baseline DLQI score in the semaglutide group was 14 (IQR = 5) at the beginning of the study, and after 12 weeks of treatment the median DLQI score was 4 (IQR = 4; p = 0.002)). The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values (p < 0.05). A significant decrease in the body mass index (BMI) value in the semaglutide-treated group was also identified, as well as a significant decrease in the level of low-density cholesterol (LDL) (p < 0.05). In conclusion, semaglutide, based on its systemic anti-inflammatory characteristics, could contribute to the treatment of psoriatic obese patients with T2DM.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese adults with psoriasis and type 2 diabetes, the median PASI score fell from 21 to 10 after 12 weeks of semaglutide.

    In plain wordsIn obese adults with psoriasis and type 2 diabetes, psoriasis severity scores fell after 12 weeks of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreasePASI score change
    Study

    n = 15

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Median PASI
    21 score
    baseline
    Median PASI
    10 score
    week 12

    Source sentences

    Summary
    The results demonstrated that the severity of the clinical picture of psoriasis, determined by the Psoriasis Area and Severity Index (PASI) score, was significantly better after the administration of semaglutide (the median baseline PASI score in patients treated with semaglutide was 21 (IQR = 19.8), while after 12 weeks of therapy the score was 10 (IQR = 6; p = 0.002).
    1 context sentence
    Summary · context
    This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese adults with psoriasis and type 2 diabetes, the median DLQI score fell from 14 to 4 after 12 weeks of semaglutide, which means better quality of life.

    In plain wordsIn obese adults with psoriasis and type 2 diabetes, skin-related quality of life improved after 12 weeks of semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseDLQI score change
    Study

    n = 15

    Outcome group
    Skin and hair · Skin and wound
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Median DLQI
    14 score
    baseline
    Median DLQI
    4 score
    week 12

    Source sentences

    Summary
    Also, the quality of life in the group of patients who received the drug, measured by the Dermatology Life Quality Index (DLQI), improved significantly after 3 months (a median baseline DLQI score in the semaglutide group was 14 (IQR = 5) at the beginning of the study, and after 12 weeks of treatment the median DLQI score was 4 (IQR = 4; p = 0.002)).
    1 context sentence
    Summary · context
    This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16).
  3. 03HumanRandomized controlled trialEfficacy outcome

    In obese adults with psoriasis and type 2 diabetes, semaglutide significantly decreased serum IL-6.

    In plain wordsIn obese adults with psoriasis and type 2 diabetes, semaglutide lowered the blood inflammation marker IL-6.

    Peptide
    Semaglutide
    Outcome
    DecreaseSerum IL-6
    Study

    n = 15

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values (p < 0.05).
    1 context sentence
    Summary · context
    This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16).
  4. 04HumanRandomized controlled trialEfficacy outcome

    In obese adults with psoriasis and type 2 diabetes, semaglutide significantly decreased CRP.

    In plain wordsIn obese adults with psoriasis and type 2 diabetes, semaglutide lowered the blood inflammation marker CRP.

    Peptide
    Semaglutide
    Outcome
    DecreaseC-reactive protein
    Study

    n = 15

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The use of semaglutide led to a significant decrease in pro-inflammatory cytokines in the serum (IL6), as well as a significant decrease in CRP values (p < 0.05).
    1 context sentence
    Summary · context
    This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16).
  5. 05HumanRandomized controlled trialEfficacy outcome

    In obese adults with psoriasis and type 2 diabetes, BMI decreased significantly in the semaglutide group.

    In plain wordsIn obese adults with psoriasis and type 2 diabetes, body mass index fell with semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index
    Study

    n = 15

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    A significant decrease in the body mass index (BMI) value in the semaglutide-treated group was also identified
    1 context sentence
    Summary · context
    This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16).
  6. 06HumanRandomized controlled trialEfficacy outcome

    In obese adults with psoriasis and type 2 diabetes, LDL cholesterol decreased significantly in the semaglutide group.

    In plain wordsIn obese adults with psoriasis and type 2 diabetes, LDL cholesterol fell with semaglutide.

    Peptide
    Semaglutide
    Outcome
    DecreaseLDL cholesterol
    Study

    n = 15

    Outcome group
    Lipids · Cardiovascular
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    as well as a significant decrease in the level of low-density cholesterol (LDL) (p < 0.05).
    1 context sentence
    Summary · context
    This randomized clinical study was conducted on 31 psoriatic patients with T2DM that were randomized into two groups: one that received semaglutide during the 12-week trial (n = 15), while the second was control (n = 16).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.